A Phase II Window-of-opportunity Study of Preoperative Therapy With Pazopanib (Votrient) in High-risk Soft Tissue Sarcoma.
Latest Information Update: 07 Sep 2023
At a glance
- Drugs Pazopanib (Primary)
- Indications Soft tissue sarcoma
- Focus Biomarker; Therapeutic Use
- Acronyms NOPASS
- 30 Jan 2014 According to ClinicalTrials.gov record, planned End Date changed from 1 Nov 2016 to 1 Jun 2018.
- 28 May 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2011-003745-18).
- 28 May 2012 Actual initiation date 22 May 2012 added as reported by EudraCT.